2018-05-01T14:18:44-05:00 2017-12-31 050409384 KAHN LITWIN RENZA & CO LTD 800 SOUTH STREET SUITE 300 WALTHAM MA 02453 990 2017-01-01 206745475 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION ADEN 7812489699 PO BOX 442 NEEDHAM MA 02494 JEFFREY A KAUFMAN EXECUTIVE DIRECTOR 7812489699 2018-05-01 1 DEBORAH A HOPKINS P00167843 7815478800 2017 2022-09-23 18:48:47Z JEFFREY A KAUFMAN PO BOX 442 NEEDHAM MA 02494 1602683 0 X WWW.ACCRF.ORG X 2005 MA SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA. 7 6 1 0 0 0 1087972 1329755 0 107991 10503 7996 1398 156941 1099873 1602683 1569525 559951 0 0 231289 81208 0 0 832 301170 523569 2101984 1164728 -1002111 437955 1563125 1623360 1245381 867661 317744 755699 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE. 0 0 257994 225813 SPECIMENS AND MODELS: ACCRF SUPPORTS AND COORDINATES THE DEVELOPMENT AND DISTRIBUTION OF BIOBANKING, CELL LINE AND ANIMAL MODEL RESOURCES FOR RESEARCHERS. THESE RESOURCES ARE THE BUILDING BLOCKS UPON WHICH ALL BASIC, TRANSLATIONAL AND CLINICAL RESEARCH ARE CONSTRUCTED. 283560 250805 BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY THE MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEELS OF THE DISEASE. 578911 83333 107991 TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL BENEFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS. 1120465 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 1 1 0 0 MA NY CA CT FL MI NC NH NY OH PA VA X MARNIE A KAUFMAN 7814491757 60 SAVOY ROAD NEEDHAM MA 02492 X JEFFREY A KAUFMAN EXECUTIVE DIRECTOR 50.00 X X 0 0 0 RALPH MOLLIS TREASURER 5.00 X X 0 0 0 ELISABETH BAKRI DIRECTOR (AS OF 6/17) 5.00 X 0 0 0 THOMAS DILENGE DIRECTOR 5.00 X 0 0 0 KARA GELB DIRECTOR 5.00 X 0 0 0 MARNIE A KAUFMAN DIRECTOR 25.00 X 0 0 0 DOUGLAS MEYER DIRECTOR 5.00 X 0 0 0 0 0 0 0 0 0 0 0 1329755 1329755 RESEARCH STUDIES 621500 107991 107991 107991 7996 7996 PY GRANTS RETURNED 900099 156941 156941 156941 1602683 107991 0 164937 509951 509951 50000 50000 77312 73351 3169 792 3896 3696 160 40 18175 18175 4096 4096 29467 17815 11652 43 43 3915 3915 3384 3384 RESEARCH STUDIES EXPENS 410212 410212 DRUG SCREENING EXPENSE 51525 51525 LICENSES AND FEES 1752 1752 STAFF DEVELOPMENT 1000 1000 1164728 1120465 43431 832 293711 289860 1267104 1308897 15093 2310 9510 1563125 1623360 23478 400236 1221903 455750 11675 1245381 867661 X 317744 755699 317744 755699 1563125 1623360 437955 0 X 0 1 X 1 0 X 531408 483168 1667904 1087972 1329755 5100207 531408 483168 1667904 1087972 1329755 5100207 667067 4433140 5333 6303 3424 10503 7996 33559 156941 156941 5290707 182886 0.83790 0.92140 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 1576242 130500 130500 1445742 156941 156941 1602683 1138287 130500 -156941 -26441 1164728 0 1164728 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH THEIR TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE FOUNDATION ANNUALLY FILES IRS FORM 990 - RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. PART XI, LINE 4B - OTHER ADJUSTMENTS: PRIOR YEAR GRANTS RETURNED 156,941. PART XII, LINE 2D - OTHER ADJUSTMENTS: PRIOR YEAR GRANTS RETURNED -156,941. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUPPORT FOR RESEARCH RELATING TO ADENOID CYSTIC CARCINOMA 25000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUPPORT FOR RESEARCH RELATING TO ADENOID CYSTIC CARCINOMA 25000 0 0 0 0 0 0 50000 0 50000 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT FOR PETER MACCALLUM MYB DNA VACCINE 25000 CHECK OR FUND TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT FOR 68GA-PSMA-PET/CT IMAGING FOR ADENOID CYSTIC CARCINOMA 25000 CHECK OR FUND TRANSFER 2 0 0 0 0 0 0 PART I, LINE 2: ALL FOREIGN GRANTS ARE MADE TO MAJOR RESEARCH INSTITUTIONS OR HOSPITALS WITH INTERNATIONAL REPUTATIONS. IN ADDITION TO INTERIM WRITTEN REPORTS ON RESEARCH PROJECTS AND A FINAL REPORT FOLLOWING PROJECT COMPLETION, ACCRF ANNUALLY MEETS WITH EACH OF THE FOREIGN GRANTEES TO RECEIVE AN ORAL REPORT ON THE RESEARCH PROJECTS. 1 BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 900656139 501(C)(3) 82500 SUPPORT OF DEVELOPMENT OF NOTCH-RELATED DIAGNOSTICS IN ADENOID CYSTIC CARCINOMA CONQUER CANCER FOUNDATION 2318 MILL ROAD 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 25000 SUPPORT OF ASCO CONQUER CANCER FOUNDATION - CAREER DEVELOPMENT AWARD GEORGETOWN UNIVERSITY 3700 O STREET NW WASHINGTON DC 20057 530196603 501(C)(3) 165480 SUPPORT FOR DEVELOPMENT OF PATIENT TISSUE-DERIVED MODEL SYSTEMS FOR ADENOID CYSTIC CARCINOMA M D ANDERSON CANCER CENTER P O BOX 4486 HOUSTON TX 772104486 746001118 501(C)(3) 140000 SUPPORT FOR IMMUNOHISTOCHEMICAL STUDIES OF ADENOID CYSTIC CARCINOMA MASSACHUSETTS EYE AND EAR INFIRMARY 243 CHARLES STREET BOSTON MA 02144 042103591 501(C)(3) 52000 SUPPORT FOR ADENOID CYSTIC CARCINOMA TUMOR BIOREPOSITORY AND REGISTRY MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 19971 SUPPORT FOR STUDY OF TARGETING TRANSCRIPTION FACTORS IN ADENOID CYSTIC CARCINOMA UNIVERSITY OF FLORIDA PO BOX 115500 GAINESVILLE FL 326115500 596002052 501(C)(3) 25000 SUPPORT OF SALIVARY GLAND TUMOR WORKSHOP 7 PART I, LINE 2: ACCRF TYPICALLY REQUIRES INTERIM REPORTING ON RESEARCH PROJECTS EVERY SIX MONTHS AS WELL AS A FINAL REPORT FOLLOWING PROJECT COMPLETION. FORM 990, PART VI, SECTION A, LINE 2 THE EXECUTIVE DIRECTOR, JEFFREY A. KAUFMAN, IS MARRIED TO A DIRECTOR ON THE BOARD, MARNIE A. KAUFMAN. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY MANAGEMENT. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL DIRECTORS. THE DIRECTORS ARE ASKED IF THEY HAVE ANY QUESTIONS OR COMMENTS AND A GENERAL REVIEW OF THE FORM IS CONDUCTED BY MANAGEMENT. REVISIONS AND CORRECTIONS ARE MADE AS NECESSARY. SUBSEQUENTLY, THE FORM IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C A FORMAL PROCESS IS UNDERTAKEN EACH YEAR TO MONITOR AND ENFORCE THE CONFLICT OF INTEREST POLICY CONTAINED WITHIN THE BYLAWS. EACH JANUARY, AN ANNUAL SURVEY ON CONFLICTS OF INTEREST IS COMPLETED BY EVERY DIRECTOR AND OFFICER COVERING THE PRIOR CALENDAR YEAR. ALL BUSINESS RELATIONSHIPS, IF ANY, ARE REPORTED TO THE BOARD OF DIRECTORS. EXCLUDING ANY INTERESTED PARTIES, A MAJORITY OF REMAINING DIRECTORS DETERMINES WHETHER A CONFLICT OF INTEREST HAS OCCURRED AND WHETHER A MORE ADVANTAGEOUS TRANSACTION IS AVAILABLE TO THE FOUNDATION THAT WOULD NOT LEAD TO A CONFLICT OF INTEREST. THE BOARD IS CHARGED WITH TAKING APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION IN THE CASE OF A VIOLATION OF THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15A A FORMAL STRATEGIC REVIEW, OBJECTIVE SETTING AND PERFORMANCE REVIEW PROCESS IS UNDERTAKEN EACH YEAR. THE BOARD OF DIRECTORS REVIEWS THE PERFORMANCE OF THE ORGANIZATION AND EXECUTIVE DIRECTOR, BASED ON GOALS AND OBJECTIVES PREVIOUSLY AGREED UPON DURING THE PRIOR CALENDAR YEAR AND ON A PERFORMANCE REPORT SUBMITTED BY THE EXECUTIVE DIRECTOR IN ADVANCE. THE INDEPENDENT DIRECTORS OF THE BOARD MEET SEPARATELY TO ASSESS THE EXECUTIVE DIRECTOR'S PERFORMANCE, AGREE ON A PROCESS TO INFORM THE EXECUTIVE DIRECTOR OF ANY AREAS OF NEEDED IMPROVEMENT, AND AGREE UPON A MERIT AND/OR COST OF LIVING SALARY INCREASE FOR THE DIRECTOR, SUBJECT TO AVAILABILITY OF FUNDS AND MAINTENANCE OF AN APPROPRIATE RATIO BETWEEN SUCH SALARY AND ACCRF FUNDRAISING/REVENUE TOTALS IN ANY GIVEN YEAR. THE EXECUTIVE DIRECTOR CHOSE TO NOT RECEIVE ANY COMPENSATION DURING 2017. THE BOARD OF DIRECTORS SETS PERFORMANCE OBJECTIVES AND METRICS FOR THE ORGANIZATION AND THE EXECUTIVE DIRECTOR FOR THE CURRENT CALENDAR YEAR. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS (ARTICLES OF INCORPORATION AND BY-LAWS), ITS CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. THE ORGANIZATION WILL MAIL COPIES UPON REQUEST OR PROVIDE COPIES TO THOSE WHO COME TO THE ADMINISTRATIVE OFFICES DURING NORMAL BUSINESS HOURS.